Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 2, 112-122, February 2005; doi:10.1634/theoncologist.10-2-112
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugarbaker, P. H.
Right arrow Articles by Yoo, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugarbaker, P. H.
Right arrow Articles by Yoo, D.

Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy

Paul H. Sugarbakera, Jorge Torres Morab, Pablo Carmignania, O. Anthony Stuarta, Dal Yooa

a Washington Cancer Institute, Washington, DC, USA; b Hospital Regional Valentin Gomez Farias, Guadalajara, Mexico

Correspondence: Paul H. Sugarbaker, M.D., F.A.C.S., F.R.C.S., Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 110 Irving St., NW Washington, DC 20010, USA. Telephone: 202-877-3908; Fax: 202-877-8602; e-mail: Paul.Sugarbaker{at}medstar.net

A new strategy currently under evaluation in patients with peritoneal carcinomatosis from gastrointestinal and gynecologic cancers is perioperative intraperitoneal chemotherapy. Although results to date show benefit to carefully selected groups of patients, continued local-regional failure is seen in many treated patients. Continued clinical and laboratory research efforts to improve local-regional effects are desired. The chemotherapeutic agents that have been used in the past or are currently being tested were reviewed. Their pharmacologic properties and clinical features were collected from the medical literature and are reviewed in the text. An organized presentation of available data concerning the drugs available for perioperative intraperitoneal chemotherapy for peritoneal surface malignancy was made. From this review, new possibilities for improved doses, schedules, and drug combinations for perioperative intraperitoneal chemotherapy may become important in future clinical studies. Continued optimal utilization of intraperitoneal chemotherapy treatments in the operating room with hyperthermia or normothermic treatment in the early postoperative period is desirable. Innovative treatment strategies can improve the outcome of patients with peritoneal surface malignancy.

Key Words. Pseudomyxoma peritonei • Peritoneal mesothelioma • Colorectal cancer • Peritoneal carcinomatosis • AUC ratio • Peritoneal surface malignancy • Cytoreductive surgery




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
D. C. Gammon, T. Dutton, B. Piperdi, J. Zybert, S. H. Wolfe, E. Nguyen, D. Sbat, V. G. Pillarisetty, M. Sullivan, and G. F. Whalen
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis
Am. J. Health Syst. Pharm., July 1, 2009; 66(13): 1186 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
W Riley
BelmontTM Hyperthermia Pump in the conduct of intra-operative heated chemotherapy
Perfusion, March 1, 2009; 24(2): 115 - 118.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. Zellos, W. G. Richards, L. Capalbo, M. T. Jaklitsch, L. R. Chirieac, B. E. Johnson, R. Bueno, and D. J. Sugarbaker
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 453 - 458.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Bijelic, A. Jonson, and P. H. Sugarbaker
Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer
Ann. Onc., December 1, 2007; 18(12): 1943 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Pespeni, M. Hodnett, K. S. Abayasiriwardana, J. Roux, M. Howard, V. C. Broaddus, and J.-F. Pittet
Sensitization of Mesothelioma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Heat Stress via the Inhibition of the 3-Phosphoinositide-Dependent Kinase 1/Akt Pathway
Cancer Res., March 15, 2007; 67(6): 2865 - 2871.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
P. H Sugarbaker, O. A. Stuart, and D. Yoo
Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy
Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 111 - 119.
[Abstract] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement